Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
NU E Power Corp. Announces Completion of Unwinding its Acquisition of Blu Dot Systems Inc. (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor... see more

Recent & Breaking News (NDAQ:MRKR)

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

GlobeNewswire February 18, 2026

Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics' MAR-T Cell Technology

GlobeNewswire January 26, 2026

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

GlobeNewswire January 5, 2026

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire November 14, 2025

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

GlobeNewswire November 5, 2025

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

GlobeNewswire November 3, 2025

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

GlobeNewswire October 6, 2025

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire August 28, 2025

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

GlobeNewswire August 26, 2025

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

GlobeNewswire July 30, 2025

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

GlobeNewswire June 17, 2025

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

GlobeNewswire May 20, 2025

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

GlobeNewswire May 19, 2025

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

GlobeNewswire April 1, 2025

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

GlobeNewswire March 31, 2025

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

GlobeNewswire February 25, 2025

Marker Therapeutics Announces $16.1 Million Private Placement

GlobeNewswire December 19, 2024

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

GlobeNewswire December 19, 2024

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

GlobeNewswire December 17, 2024

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

GlobeNewswire December 10, 2024

Podcasts